TW371303B - 5-phenyl-3-(piperidin-4-YL)-1,3,4-oxadiazol-2(3H)-one derivatives, their preparation and their application in therapeutics - Google Patents

5-phenyl-3-(piperidin-4-YL)-1,3,4-oxadiazol-2(3H)-one derivatives, their preparation and their application in therapeutics

Info

Publication number
TW371303B
TW371303B TW085113594A TW85113594A TW371303B TW 371303 B TW371303 B TW 371303B TW 085113594 A TW085113594 A TW 085113594A TW 85113594 A TW85113594 A TW 85113594A TW 371303 B TW371303 B TW 371303B
Authority
TW
Taiwan
Prior art keywords
group
phenyl
piperidin
therapeutics
application
Prior art date
Application number
TW085113594A
Other languages
English (en)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruuz Laurence
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of TW371303B publication Critical patent/TW371303B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW085113594A 1995-11-09 1996-11-07 5-phenyl-3-(piperidin-4-YL)-1,3,4-oxadiazol-2(3H)-one derivatives, their preparation and their application in therapeutics TW371303B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
TW371303B true TW371303B (en) 1999-10-01

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085113594A TW371303B (en) 1995-11-09 1996-11-07 5-phenyl-3-(piperidin-4-YL)-1,3,4-oxadiazol-2(3H)-one derivatives, their preparation and their application in therapeutics

Country Status (30)

Country Link
US (1) US5929089A (zh)
EP (1) EP0863897B1 (zh)
JP (1) JP4263240B2 (zh)
CN (1) CN1077891C (zh)
AR (1) AR004708A1 (zh)
AT (1) ATE181328T1 (zh)
AU (1) AU707325B2 (zh)
BG (1) BG63463B1 (zh)
BR (1) BR9611311A (zh)
CA (1) CA2236357C (zh)
CO (1) CO4770968A1 (zh)
CZ (1) CZ287268B6 (zh)
DE (1) DE69602970T2 (zh)
EE (1) EE03487B1 (zh)
ES (1) ES2135934T3 (zh)
GR (1) GR3030823T3 (zh)
HK (1) HK1016165A1 (zh)
HU (1) HUP0001168A3 (zh)
IL (1) IL124364A (zh)
MX (1) MX9803696A (zh)
NO (1) NO309606B1 (zh)
NZ (1) NZ321626A (zh)
PL (1) PL186204B1 (zh)
RU (1) RU2167160C2 (zh)
SI (1) SI0863897T1 (zh)
SK (1) SK282335B6 (zh)
TR (1) TR199800827T2 (zh)
TW (1) TW371303B (zh)
UA (1) UA50748C2 (zh)
WO (1) WO1997017345A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
FR2763068B1 (fr) * 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
WO1998050383A1 (fr) * 1997-05-06 1998-11-12 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
ATE310566T1 (de) 1998-09-18 2005-12-15 Alcon Mfg Ltd 5ht2-agoniste zur behandlung des glaukoms
AU5259100A (en) * 1999-04-28 2000-11-10 Respiratorius Ab Medicament
EP1185263A2 (en) * 1999-06-15 2002-03-13 Respiratorius AB Receptor agonists and antagonists
ES2260276T3 (es) 2000-08-08 2006-11-01 Ortho-Mcneil Pharmaceutical, Inc. Ariloxialquilaminas no imidazolicas como ligandos del receptor h3.
KR100852362B1 (ko) 2000-08-08 2008-08-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 비-이미다졸 아릴옥시피페리딘
AU2001281119A1 (en) 2000-08-08 2002-02-18 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
DE60234453D1 (de) 2001-07-02 2009-12-31 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
ATE450508T1 (de) * 2001-09-14 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE479655T1 (de) 2001-09-14 2010-09-15 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
JP2005511764A (ja) 2001-12-14 2005-04-28 アルコン，インコーポレイテッド 緑内障の処置のためのアミノアルキルベンゾフラン−５−オール化合物
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP2386554A1 (en) * 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
ATE538116T1 (de) * 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EA022374B1 (ru) * 2011-09-19 2015-12-30 Сувен Лайф Сайенсиз Лимитед Гетероарильные соединения в качестве лигандов 5-htрецептора

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
DK0604494T3 (da) * 1991-09-12 1999-11-29 Smithkline Beecham Plc 5-HT4-receptorantagonister
EP0625149A1 (en) * 1992-02-06 1994-11-23 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
DE69602970T2 (de) 2000-01-20
WO1997017345A1 (fr) 1997-05-15
EE9800155A (et) 1998-12-15
SI0863897T1 (en) 1999-10-31
BG102412A (en) 1999-08-31
PL186204B1 (pl) 2003-11-28
EP0863897A1 (fr) 1998-09-16
SK59998A3 (en) 1998-11-04
DE69602970D1 (de) 1999-07-22
AR004708A1 (es) 1999-03-10
UA50748C2 (uk) 2002-11-15
CA2236357C (en) 2006-10-17
ATE181328T1 (de) 1999-07-15
NO982092L (no) 1998-06-29
CO4770968A1 (es) 1999-04-30
CN1202169A (zh) 1998-12-16
EE03487B1 (et) 2001-08-15
CN1077891C (zh) 2002-01-16
NO309606B1 (no) 2001-02-26
AU7500196A (en) 1997-05-29
JP2000500125A (ja) 2000-01-11
GR3030823T3 (en) 1999-11-30
CZ142198A3 (cs) 1998-08-12
BG63463B1 (bg) 2002-02-28
MX9803696A (es) 1998-09-30
PL326671A1 (en) 1998-10-12
CA2236357A1 (en) 1997-05-15
NO982092D0 (no) 1998-05-07
HUP0001168A2 (hu) 2001-04-28
BR9611311A (pt) 1999-06-29
US5929089A (en) 1999-07-27
EP0863897B1 (fr) 1999-06-16
IL124364A (en) 2001-08-08
ES2135934T3 (es) 1999-11-01
RU2167160C2 (ru) 2001-05-20
AU707325B2 (en) 1999-07-08
CZ287268B6 (en) 2000-10-11
SK282335B6 (sk) 2002-01-07
JP4263240B2 (ja) 2009-05-13
NZ321626A (en) 1998-10-28
HUP0001168A3 (en) 2001-07-30
HK1016165A1 (en) 1999-10-29
IL124364A0 (en) 1998-12-06
TR199800827T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
TW371303B (en) 5-phenyl-3-(piperidin-4-YL)-1,3,4-oxadiazol-2(3H)-one derivatives, their preparation and their application in therapeutics
AU4306796A (en) Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
TW325458B (en) Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
TW347387B (en) Piperidine derivatives
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
HUP9802304A2 (hu) Piridazin-3-on-származékok, intermedierjeik, alkalmazásuk, a vegyületeket hatóanyagként tartalmazó herbicid készítmények
MX9806255A (es) Piperazinas aromaticas novedosas derivadas de cicloazanos sustituidos, metodo para preparar las mismas, composiciones farmaceuticas y uso de las mismas como farmacos.
HUP0000167A2 (hu) Pirrolvegyületek, és ezeket a vegyületeket tartalmazó spla2-inhibitor hatású gyógyszerészeti készítmények
PL338735A1 (en) Fluoropyrazole bisphenylamide based
IL105909A (en) Fungicidal compositions comprising indole derivatives, certain such novel compounds and their preparation
HUP9904682A2 (hu) Fenil-oxazol- és -tiazol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
EP0742203A3 (zh)
NZ516454A (en) Titanium compounds, preparation and use thereof
IL90309A0 (en) 6-phenyl-3-(piperazinylalkyl)-2,4(1h,3h)-pyrimidinedione derivatives,their preparation and their application in therapy
NZ515025A (en) Solvates of pymetrozine
WO2002000638A8 (en) Substituted phthalides as anti-convulsive drugs
HUP9901176A2 (hu) Eljárás 2,2'-bipirrolil-pirrometén-származékok (prodigiozinok) előállítására és intermedierjeik
IL108885A0 (en) Benzoxazine derivatives, their preparation and their application in therapy
FI932874A0 (fi) 6,7-modifierade 11b-aryl-4-estrener
BG104037A (en) 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy
EP0552489A3 (zh)
BG103810A (en) Derivatives of 5-aryl-3-(8-azabicyclo(3.2.1)oct-3-yl)-1,3,4-oxadiazol-2(3h)-on as ligands of 5-ht4 receptors
ES2044788A1 (es) Procedimiento para la obtencion de nuevos derivados de aril-heteroaril-(n-(2-(3,4-dimetoxifenil)etil)-n-metil-3-aminopropoxi)metano y sus sales fisiologicamente aceptables correspondientes.
TW356467B (en) Oxazoloquinolinone derivatives their preparation and their therapeutic application
ATE216883T1 (de) Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees